Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT02474069
- Phase
- PHASE3
- Status
- Completed
Conditions
- Moderate to Severe Plaque-type Psoriasis
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Secukinumab — DRUG
Study Details
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis. The purpose of the study is to explore the effects of dosage interval shorteng to achieve PASI 90 at week 32 for patients who had less than almost clear skin at week 16.
Key Dates
- Start date
- Feb 8, 2015
- Status verified
- Apr 2019
- Primary completion
- Sep 15, 2016
- Completion
- Sep 15, 2016
Study Design
- Enrollment
- 772 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Secukinumab Interval Shortening
- Active Comparator: Secukinumab 4-weekly
Primary Outcome Measure
Number of Participants With PASI 90 Response at Week 32 [ Time Frame: at 32 weeks ]